Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
1.280
+0.342 (36.46%)
At close: Dec 20, 2024, 4:00 PM
1.240
-0.040 (-3.13%)
After-hours: Dec 20, 2024, 7:59 PM EST

Xilio Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Selling, General & Admin
24.662729.9523.8610.654.77
Research & Development
44.1152.1459.251.1943.9114.26
Operating Expenses
68.7779.1389.1575.0454.5619.03
Operating Income
-64.15-79.13-89.15-75.04-54.56-19.03
Interest Expense
-0.2-0.7-0.8-0.6-0.6-
Other Non Operating Income (Expenses)
2.483.431.73-0.16-0.061.72
Pretax Income
-62.8-76.4-88.22-75.8-55.22-17.31
Net Income
-62.8-76.4-88.22-75.8-55.22-17.31
Net Income to Common
-62.8-76.4-88.22-75.8-55.22-17.31
Shares Outstanding (Basic)
442727610
Shares Outstanding (Diluted)
442727610
Shares Change (YoY)
61.00%0.38%388.59%970.34%27.97%-
EPS (Basic)
-1.42-2.78-3.22-13.52-105.42-42.29
EPS (Diluted)
-1.42-2.78-3.22-13.52-105.42-42.29
Free Cash Flow
-17.68-69.11-77.59-81.85-38.28-18.56
Free Cash Flow Per Share
-0.40-2.51-2.83-14.60-73.08-45.34
EBITDA
-62.43-77.23-87.3-73.55-53.5-18.79
D&A For EBITDA
1.721.91.851.51.070.24
EBIT
-64.15-79.13-89.15-75.04-54.56-19.03
Source: S&P Capital IQ. Standard template. Financial Sources.